Allergan, Inc. Underwriting Agreement September 7, 2010Underwriting Agreement • September 14th, 2010 • Allergan Inc • Pharmaceutical preparations • New York
Allergan, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $650,000,000 principal amount of the Notes of the Company, specified above (the “Securities”). Banc of America Securities LLC, Goldman, Sachs & Co., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. Incorporated have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Notes.
ALLERGAN, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of September 14, 2010 $650,000,000 3.375% Notes due 2020First Supplemental Indenture • September 14th, 2010 • Allergan Inc • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of September 14, 2010, between Allergan, Inc., a corporation existing under the laws of the State of Delaware, with offices at 2525 Dupont Drive, Irvine, California 92612 (the “Company”), and Wells Fargo Bank, National Association, a national banking association, duly organized and validly existing under the laws of the United States of America, having its corporate trust office at 707 Wilshire Blvd, 17th Floor, Los Angeles, California 90017, Attention: Corporate Trust Department, as trustee (the “Trustee”).
